Aminopterin Ready Made Solution
SIGMA/SBR00016 - 50 mg/mL in DMSO
Synonym: (S)
CAS Number: 54-62-6
Empirical Formula (Hill Notation): C19H20N8O5
Molecular Weight: 440.41
MDL Number: MFCD00036692
Linear Formula: C19H20N8O5
Product Type: Chemical
| assay | ≥85% |
| concentration | 50 mg/mL in DMSO |
| form | liquid |
| InChI | 1S/C19H20N8O5/c20-15-14-1 |
| InChI key | TVZGACDUOSZQKY-UHFFFAOYSA |
| Quality Level | 200 ![]() |
| shipped in | dry ice |
| SMILES string | OC(CC[C@@H](C(O)=O)NC(C1= |
| solubility | DMSO: 50 mg/mL |
| storage condition | protect from light |
| storage temp. | −20°C |
| Biochem/physiol Actions: | Aminopterin is a synthetic derivative of pterin. It is used as a folic acid antagonist. It competitively inhibits dihydrofolate reductase (DHFR) and blocks tetrahydrofolate synthesis. This inhibition blocks DNA, RNA and protein synthesis. Aminopterin is actively transported into cells by the folate transporter. In the cell, it is converted to a high molecular weight polyglutamate metabolite by folylpolyglutamate synthase that, in turn, binds to dihydrofolate reductase and inhibits its activity. Aminopterin-polyglutamate is degraded intracellularly by γ-glutamyl hydrolase. Aminopterin was first administered for cancer therapy, as a drug targeting metabolism, specifically in pediatric leukemia. Later on it was demonstrated to be more potent yet more toxic than methotrexate. |
| Symbol | ![]() GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301 - H360 |
| Precautionary statements | P201 - P280 - P301 + P330 + P331 + P310 - P308 + P313 |
| RIDADR | UN 2810 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | 188.6 °F |
| Flash Point(C) | 87 °C |
| Purity | ≥85% |
| Storage Temp. | −20°C |
| UNSPSC | 12352205 |



